



## HEROIN




Past 6 month use of heroin remained stable at 75% in the 2021 sample, (78% in 2020).



Of those who had recently consumed heroin, 81% used it weekly or more often, stable from 81% in 2020.




The median reported price for a point of heroin was \$50 in 2021 and \$50 in 2020.




Of those who could comment 79% perceived heroin to be 'easy' or 'very easy' to obtain, an increase from 59% in 2020.


## METHAMPHETAMINE




Past 6 month use of any (74%), crystal (74%), and base (n≤5) methamphetamine remained stable in 2021, whereas powder decreased (n≤5).



Of those who had recently used any form of methamphetamine, 68% used it at least weekly, stable from 71% in 2020.



The median reported price for a point of crystal methamphetamine was \$50 in 2021, a decrease from \$60 in 2020.



Of those who could comment, 84% perceived crystal methamphetamine to be 'easy' or 'very easy' to obtain in 2021, an increase from 48% in 2020.


## OTHER DRUGS

### Non-prescribed morphine



Past 6 month use of non-prescribed morphine was stable at 6% in the 2020 sample and 9% in 2021.

### Non-prescribed fentanyl




Past 6 month use of non-prescribed fentanyl was stable at 8% in the 2020 sample to 7% in 2021.

### Non-prescribed pregabalin




Past 6 month use of non-prescribed pregabalin was stable at 11% in the 2020 sample and 12% in 2021.

### GHB/GBL/1,4-BD




Past 6 month use of GHB/GBL/1,4-BD was stable from 9% in the 2020 sample to 16% in 2021.


## CANNABIS




Past 6 month use of any cannabis was stable at 64% in the 2020 sample and 65% in 2021.



Of those who had consumed cannabis recently, under half reported daily use (45%).



Of people who had consumed cannabis in the last 6 months, 98% had smoked it.




Of those who could comment 77% perceived hydro and 61% perceived bush to be 'easy' or 'very easy' to obtain.


## 2021 SAMPLE CHARACTERISTICS




In 2021, 150 people from Sydney, NSW participated in IDRS interviews.



The mean age in 2021 was 47, and 70% identified as male.




In the 2021 sample, 89% were unemployed and 8% had no fixed address.




Participants were recruited on the basis that they had injected drugs at least monthly in the previous 6 months.

## INJECTING RELATED RISKS AND HARMS




In 2021, 7% of the IDRS sample reported receptive needle sharing, and 9% reported distributive needle sharing.



The number of people who re-used their own needles remained stable from 46% in 2020 to 39% in 2021.




In the NSW sample, 26% of participants reported injecting someone else after injecting themselves.




In 2021, 32% of the NSW sample reported having an injection-related health issue in the month preceding interview.


## OTHER HARMS AND HELP-SEEKING




IDRS participants' use of drugs the day before interview participation, 2021.



In the 2021 sample, 24% had experienced a non-fatal overdose in the previous 12 months and 50% were currently in drug treatment.




In the sample, 47% self reported a mental health problem in the six months prior to interview, and 25% had seen a mental health professional.




Of those who commented, the three most common mental health issues reported were depression (66%), anxiety (36%) and PTSD (19%).


## NALOXONE AND HARM REDUCTION



IDRS participants' knowledge of, and participation in, the take-home naloxone program remained stable in 2021.



Of those who reported having heard of naloxone, 30% had used naloxone to resuscitate someone who had overdosed.



Of those who reported ever accessing naloxone, 31% received intramuscular naloxone, 48% intranasal naloxone and 21% both.



In 2021, 13% of the sample reported that they or someone else had tested the content and/or purity of their illicit drugs in Australia in the past year.